To our knowledge, this is the first exploratory study showing the association of the genetic variants DRD4-VNTR and DAT1-VNTR, together with an MLGP score analysis, with an increased risk of developing obesity, diastolic arterial hypertension, and hypertriglyceridemia in patients treated with SGAs. This evidence concerns the gene SLC6A3 and Obesity.